会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
    • 化合物及其调节方法及其适应症
    • WO2008080015A3
    • 2008-10-02
    • PCT/US2007088443
    • 2007-12-20
    • PLEXXIKON INCIBRAHIM PRABHA NBREMER RYANZHANG CHAOZHANG JIAZHONGHIRTH KLAUS-PETERWU GUOXIANZHU HONGYAO
    • IBRAHIM PRABHA NBREMER RYANZHANG CHAOZHANG JIAZHONGHIRTH KLAUS-PETERWU GUOXIANZHU HONGYAO
    • C07D471/04A61K31/437A61P25/00A61P29/00A61P35/00
    • C07D471/04
    • Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases. Formula (II), all salts, prodrugs, tautomers, and isomers thereof, wherein: t is 0, 1, 2, or 3; Z 2 is N or CR 12 ; Z 6 is N or CR 16 ; L 4 is selected from the group consisting of -(CR 10 R 11 ) P -NR 25 -(CR 10 R 11 ) q- , -(CR 10 R 11 ) p -X-(CR 10 R 11 ) q , -(CR 10 R 11 ) p- C(X)-(CR 10 R 11 ) q , -(CR 10 R 11 ) p -S(O)-(CR 10 R 11 ) q -, -(CR 10 R 11 ) p -S(O) 2 -(CR 10 R 11 ) q -, -(CR 10 R 11 ) p -C(X)NR 25 -(CR 10 R 11 ) q -, -(CR 10 R 11 ) p -S(O) 2 NR 25 -(CR 10 R 11 ) q -,-(CR 10 R 11 ) p -NR 25 C(X)-(CR 10 R11) q -, -(CR 10 R 11 ) p -NR 25 S(O) 2 -(CR 10 R 11 ) q -, -(CR 10 R 11 ) p -NR 25 -(CR 10 R 11 ) q -, and -(CR 10 R 11 ) p -NR 25 S(O) 2 NR 25 -(CR 10 R11) q -; p and q are independently 0, 1, or 2 provided, however, that at least one of p and q is O.
    • 描述了对蛋白激酶有活性的化合物,以及使用这些化合物治疗与蛋白激酶异常活性相关的疾病和病症的方法。 式(II),其所有盐,前药,互变异构体和异构体,其中:t为0,1,2或3; Z 2是N或CR 12; Z 6是N或CR 16; L 4选自 - (CR 10)11 - , - - - (CR 10)11 - (CR 10) - - (CR 10) q + q - (CR 11)11, - (CR 11) 10 - [R 11 点 - C(X) - (CR 10 - [R 11 10 - [R 11 p -C(X)NR 25 - (CR 10 < 其中R 1,R 2,R 2,R 3,R 3,R 3, SUB> -S(O) 2 NR 25 - (CR 10 - [R 11 q < / SUB> - , - (CR 10 - [R 11 p -NR 25 C(X) - ( CR 10 R 11) - , - (CR 10)11 - -NR 25 S(O) 2 - (CR 10 - [R 11 (CR 10) - (CR 10) - (CR 11) 其中 - (CR 10)11 - 和 - (CR 10)11 - SUB> p -NR 25 S(O) 2 NR 25 - (CR 10 R11 ) q - ; p和q独立地为0,1或2,但是p和q中的至少一个为O.
    • 10. 发明申请
    • COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
    • 化合物及其调节方法及其适应症
    • WO2011079133A3
    • 2011-11-17
    • PCT/US2010061601
    • 2010-12-21
    • PLEXXIKON INCIBRAHIM PRABHA NWU GUOXIANLIN JACKSPEVAK WAYNECHO HANNAEWING TODDZHANG CHAO
    • IBRAHIM PRABHA NWU GUOXIANLIN JACKSPEVAK WAYNECHO HANNAEWING TODDZHANG CHAO
    • C07D471/04A61K31/437A61P35/00
    • C07D471/04A61K31/437A61K31/497A61K31/498A61K31/506A61K31/519C07D519/00
    • Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on each of B-Raf, B-Raf V600E and c-Raf-1 protein kinase. In certain aspects and embodiments, the described compounds are active in inhibiting proliferation of a Ras mutant cell line. Also described are methods of use thereof to treat diseases and conditions, including melanoma, glioma, glioblastoma, pilocytic astrocytoma, liver cancer, biliary tract cancer, cholangiocarcinoma, colorectal cancer, lung cancer, bladder cancer, gallbladder cancer, breast cancer, pancreatic cancer, thyroid cancer, kidney cancer, ovarian cancer, adrenocortical cancer, prostate cancer, gastrointestinal stromal tumors, medullary thyroid cancer, tumor angiogenesis, acute myeloid leukemia, chronic myelomonocytic leukemia, childhood acute lymphoblastic leukemia, plasma cell leukemia, and multiple myeloma.
    • 其化合物及其盐,其制剂,其缀合物,其衍生物,其形式及用途。 在某些方面和实施方案中,所述的化合物或其盐,其制剂,其缀合物,其衍生物,其形式在B-Raf,B-Raf V600E和c-Raf-1蛋白激酶中的每一个上都是活性的。 在某些方面和实施方案中,所述化合物在抑制Ras突变细胞系的增殖中是有活性的。 还描述了其用于治疗疾病和病症的方法,包括黑素瘤,神经胶质瘤,成胶质细胞瘤,纤维细胞性星形细胞瘤,肝癌,胆道癌,胆管癌,结肠直肠癌,肺癌,膀胱癌,胆囊癌,乳腺癌,胰腺癌, 甲状腺癌,肾癌,卵巢癌,肾上腺皮质癌,前列腺癌,胃肠道间质瘤,甲状腺髓样癌,肿瘤血管生成,急性骨髓性白血病,慢性骨髓单核细胞白血病,儿童急性淋巴细胞性白血病,浆细胞白血病和多发性骨髓瘤。